MASTERINVEST Kapitalanlage GmbH Acquires Shares of 14,942 Medtronic PLC $MDT

MASTERINVEST Kapitalanlage GmbH bought a new position in shares of Medtronic PLC (NYSE:MDT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 14,942 shares of the medical technology company’s stock, valued at approximately $1,302,000.

A number of other large investors have also recently made changes to their positions in MDT. 1248 Management LLC purchased a new stake in Medtronic in the 1st quarter valued at about $26,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic during the second quarter worth approximately $27,000. Twin Tree Management LP bought a new stake in shares of Medtronic during the first quarter valued at approximately $29,000. Activest Wealth Management raised its stake in shares of Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares in the last quarter. Finally, GFG Capital LLC purchased a new stake in shares of Medtronic in the second quarter valued at approximately $36,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MDT has been the topic of several research reports. Weiss Ratings restated a “buy (b)” rating on shares of Medtronic in a report on Monday, December 8th. Daiwa Capital Markets raised their price target on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Royal Bank Of Canada increased their target price on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Finally, Citigroup boosted their price target on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.44.

Medtronic Price Performance

MDT opened at $99.86 on Monday. The firm has a market capitalization of $128.02 billion, a PE ratio of 26.92, a price-to-earnings-growth ratio of 2.63 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The business’s 50-day moving average is $97.27 and its two-hundred day moving average is $92.96. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the business earned $1.26 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is 76.55%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.